Ultomiris, a product of Alexion Pharmaceuticals, has recently been studied in a Phase 3 clinical trial. This study was intended to ultomiris' effect on life-threatening complications of atypical hemolytic uremic…
-150x150.jpg)
Neurotrope is launching a long term Phase 2 trial of Bryostatin-1, which is a treatment for Alzheimer's disease. The National Institutes of Health (NIH) will be joining this study, giving…
As reported in Med Gadget, Medtech company ’11 Health’ has made virtual healthcare affordable this quarantine season, providing patients with severe chronic digestive disorders 12 weeks of free access on their…
Enanta Pharmaceuticals has recently released the results from the second phase of its INTREPID trial, which studied EDP-305 as a treatment for primary biliary cholangitis (PBC). The results were positive,…
Protalix BioTherapeutics has recently announced the results from the third phase of the BRIDGE trial, which evaluated pegunigalsidase alfa for the treatment of Fabry disease. As these results were positive,…
Axcella, a biotechnology company based out of Cambridge, Massachusetts, has released the results of AXA1125-003. According to Biotech 365, this study showed positive results for those with non-alcoholic fatty liver…
Want to learn more about recognizing symptoms and diagnosing patients? In a MedPage article, authors encourage readers to follow along on a case study to understand why a 58-year-old…
According to an article in Healio, the immunosuppressing drug voclosporin was found to be effective in stimulating renal responses in patients with lupus nephritis. About Lupus Nephritis Lupus nephritis…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
